Loading…
BioVie Inc. is projected to rise to $2.53 by 2027, a +56% move from its current price of $1.62. BIVI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.51 | $1.62 | $1.74 | +0.03% |
| Aug 6 | $1.46 | $1.62 | $1.80 | +0.07% |
| Aug 7 | $1.43 | $1.62 | $1.84 | +0.10% |
| Aug 8 | $1.40 | $1.62 | $1.87 | +0.14% |
| Aug 9 | $1.38 | $1.62 | $1.91 | +0.17% |
| Aug 10 | $1.36 | $1.62 | $1.94 | +0.20% |
| Aug 11 | $1.34 | $1.62 | $1.97 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.34 | $1.62 | $1.97 | +0.24% |
| Week 2 | $1.24 | $1.63 | $2.13 | +0.47% |
| Week 3 | $1.17 | $1.63 | $2.27 | +0.71% |
| Week 4 | $1.12 | $1.64 | $2.39 | +0.95% |
| Week 5 | $1.07 | $1.64 | $2.51 | +1.19% |
| Week 6 | $1.03 | $1.64 | $2.62 | +1.43% |
| Week 7 | $0.9944 | $1.65 | $2.73 | +1.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company operates in Healthcare and focuses on developing treatments for complex conditions that affect the brain and liver.
Its programs include BIV201, which is in Phase 2 for the treatment of ascites due to chronic liver cirrhosis, and NE3107, which is in Phase III clinical trial for mild to moderate Alzheimer's disease, and in Phase 2 to treat Parkinson's disease as well as for the long COVID program.
The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie was incorporated in 2013 and is headquartered in Carson City, Nevada.
BioVie Inc. (BIVI) is the stock, with a current price of $1.43 and an overall market position reflected by a market cap of $10.79M and a rank of 4789.
The outlook in the provided price forecasts shows a neutral starting point in 2026 with an average price of $1.43, followed by a bullish trajectory in later years. Forecasts project the average price rising in successive years, supported by rising max prices and positive sentiment from 2027 onward.
From 2027 onward, the sentiment shifts to BULLISH, with 2030 at an average of $2.35 and continuing growth through 2040 ($4.81) and 2050 ($7.21). Max price forecasts extend to $16.59 by 2050, indicating substantial upside potential, albeit as estimates rather than guarantees.
These figures provide a framework for potential price movement over a multi-year horizon, with the understanding that actual results can differ due to market dynamics and other factors.
A major floor 58.4% below — a decisive break under it would weaken the trend.
The nearest floor, 22.2% below — buyers have tended to step in here.
The nearest ceiling, 40.1% above — a clean break opens room to run.
A major ceiling 66.3% above — clearing it would confirm fresh momentum.
Key BIVI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BIVI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.38 | Buy | $1.42 | Buy |
| MA 10 | $1.38 | Buy | $1.46 | Buy |
| MA 20 | $1.66 | Sell | $1.56 | Buy |
| MA 50 | $1.69 | Sell | $1.63 | Sell |
| MA 100 | $1.57 | Buy | $1.65 | Sell |
| MA 200 | $1.49 | Buy | $3.34 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.03 | Neutral |
| Stoch RSI (14) | 88.72 | Sell |
| CCI (20) | -32.08 | Neutral |
| Williams %R (14) | -51.85 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -14.12 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 48.15 | Neutral |
| TRIX (15) | -0.75 | Sell |
| Awesome (5,34) | -0.37 | Sell |
| Ultimate (7,14,28) | 57.47 | Neutral |
| Momentum (10) | -0.28 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.39 | Buy |
| ADX (14) | 19.57 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture shows a NEUTRAL posture, with RSI(14) at 40 indicating neither overbought nor oversold conditions.
The short-term moving averages present SMA50 at $1.68 and SMA200 at $1.50, framing a narrow range around the current price. Support is identified at $1.26 and resistance at $2.27. The 30-day range spans from $0.8834 to $2.31, and annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.06 | $1.62 | $2.59 | 0% | Neutral | |
| $1.85 | $2.53 | $3.76 | +56% | Bullish | |
| $2.08 | $3.03 | $4.80 | +87% | Bullish | |
| $1.83 | $2.82 | $4.69 | +74% | Bullish | |
| $1.67 | $2.70 | $4.67 | +66% | Bullish | |
| $1.57 | $2.65 | $4.75 | +64% | Bullish | |
| $1.49 | $2.61 | $4.83 | +61% | Bullish | |
| $1.97 | $3.61 | $6.86 | +123% | Bullish | |
| $2.13 | $4.05 | $7.90 | +150% | Bullish | |
| $2.10 | $4.15 | $8.28 | +156% | Bullish | |
| $2.46 | $5.47 | $12.00 | +238% | Bullish | |
| $3.67 | $8.15 | $18.75 | +403% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.06 | $1.62 | $2.07 | +0.00% |
| September 2026 | $1.45 | $1.76 | $2.23 | +8.49% |
| October 2026 | $1.36 | $1.67 | $2.16 | -4.94% |
| November 2026 | $1.36 | $1.69 | $2.23 | +1.38% |
| December 2026 | $1.54 | $1.94 | $2.59 | +14.60% |
Click any year to see its month-by-month BIVI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BIVI is projected to trade between $1.06 and $2.59, averaging $1.62 — a potential gain of 0% from today's $1.62. A consolidation phase looks the most probable path here.
BioVie Inc.'s 2027 outlook centres on $2.53, within a $1.85 to $3.76 range. That is up +56% on the projected 2026 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2028, BIVI could reach as high as $4.80, with a base case around $3.03 and support toward $2.08 — roughly +87% from $1.62. Buyers look set to stay in control over this stretch.
Expect BIVI to range from $1.83 to $4.69 through 2029. The $2.82 average target implies a +74% move from current prices. That is -7% versus the projected 2028 average. Momentum favours further upside here.
The BIVI price prediction for 2030 points to an average of $2.70 (low $1.67, high $4.67) — a potential gain of +66% on today's $1.62. Buyers look set to stay in control over this stretch.
In 2031, BIVI is projected to trade between $1.57 and $4.75, averaging $2.65 — a potential gain of +64% from today's $1.62. That is -2% versus the projected 2030 average. Momentum favours further upside here.
BioVie Inc.'s 2032 outlook centres on $2.61, within a $1.49 to $4.83 range. That is -1% versus the projected 2031 average. That marks a +61% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BIVI could reach as high as $6.86, with a base case around $3.61 and support toward $1.97 — roughly +123% from $1.62. Momentum favours further upside here.
Expect BIVI to range from $2.13 to $7.90 through 2034. The $4.05 average target implies a +150% move from current prices. That is up +12% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The BIVI price prediction for 2035 points to an average of $4.15 (low $2.10, high $8.28) — a potential gain of +156% on today's $1.62. Momentum favours further upside here.
In 2040, BIVI is projected to trade between $2.46 and $12.00, averaging $5.47 — a potential gain of +238% from today's $1.62. That is up +32% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioVie Inc.'s 2050 outlook centres on $8.15, within a $3.67 to $18.75 range. That is up +49% on the projected 2040 average. That marks a +403% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BIVI today (≈ 617.283951 BIVI) could be worth
$5,033.5
+$4,033.5 (+403%) by 2050 · US Dollar
Based on the average projected BIVI price of $8.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BIVIwould be worth at today's price.
$1,000 invested in BIVI on Jul 31, 2025 (≈ 166.52789 BIVI) would be worth
$269.78
-$730.22 (-73.0%) today · 0.27× · US Dollar
Based on a BIVI entry price of $6.01 vs. today's $1.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.37 | $1,182.48 | +18.2% |
| 1 month ago | $2.18 | $743.12 | -25.7% |
| 3 months ago | $1.68 | $964.29 | -3.6% |
| 6 months ago | $1.24 | $1,306.45 | +30.6% |
| 1 year ago | $6.01 | $269.78 | -73.0% |
| All time (5.0y) ago | $1,367.5 | $1.18 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BIVI forecast.
Our base-case forecast reaches $3.20 around 2033.
Implied market cap at $3.20: $24.14M
The multi-year forecast paints a bullish path after a neutral start, with a series of rising averages and notable ROIs in later years. For 2027 the avg price is $2.22 with a 55.1% ROI and a BULLISH sentiment, followed by continued upside in 2028 at $2.67 (ROI 86.9%) and 2029 at $2.50 (ROI 74.8%). By 2030 the avg is $2.35 with a 64.5% ROI, and the long-run trajectory remains bullish through 2035 (avg $3.66, ROI 156.1%).
Key later milestones include 2033 avg $3.14 with a max of $5.97 (ROI 119.6%), 2034 avg $3.59 with a max of $6.99 (ROI 150.9%), and 2035 avg $3.66 with a max of $7.31 (ROI 156.1%). The forecast accelerates to 2040, with avg $4.81 and max $10.54 (ROI 236.2%), and reaches 2050 with avg $7.21 and max $16.59 (ROI 404.3%).
These estimates are not guarantees and actual results may differ. They reflect projected upside under bullish conditions alongside inherent investment risk and uncertainty.
Tap a question to reveal the answer.
Avg $2.35, min $1.46, max $4.07, ROI 64.5%, sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and notable ROIs (e.g., 2027 ROI 55.1%, 2028 ROI 86.9%, 2033 ROI 119.6%).
Yes. The 2033 max is $5.97; 2034 max $6.99; 2035 max $7.31.
Current price $1.43; Market cap $10.79M.
Sentiment NEUTRAL; RSI14 40; SMA50 $1.68; SMA200 $1.50; support $1.26; resistance $2.27; 30-day range $0.8834-$2.31; annualized volatility 100%.
BioVie Inc. Community Discussion
0Share your BioVie Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.